+

WO2009007390A3 - 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors - Google Patents

2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2009007390A3
WO2009007390A3 PCT/EP2008/058898 EP2008058898W WO2009007390A3 WO 2009007390 A3 WO2009007390 A3 WO 2009007390A3 EP 2008058898 W EP2008058898 W EP 2008058898W WO 2009007390 A3 WO2009007390 A3 WO 2009007390A3
Authority
WO
WIPO (PCT)
Prior art keywords
inylbenz
pyraz
tyrosine kinase
kinase inhibitors
receptor tyrosine
Prior art date
Application number
PCT/EP2008/058898
Other languages
French (fr)
Other versions
WO2009007390A2 (en
Inventor
Linette Rushton
Jon James Gordon Winter
Original Assignee
Astrazeneca Ab
Linette Rushton
Jon James Gordon Winter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Linette Rushton, Jon James Gordon Winter filed Critical Astrazeneca Ab
Publication of WO2009007390A2 publication Critical patent/WO2009007390A2/en
Publication of WO2009007390A3 publication Critical patent/WO2009007390A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns pyrazine derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of G1, G2, R1, m, R2, R3, n and R4 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
PCT/EP2008/058898 2007-07-09 2008-07-09 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors WO2009007390A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0713259.0A GB0713259D0 (en) 2007-07-09 2007-07-09 Pyrazine derivatives 954
GB0713259.0 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009007390A2 WO2009007390A2 (en) 2009-01-15
WO2009007390A3 true WO2009007390A3 (en) 2009-03-19

Family

ID=38440612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/058898 WO2009007390A2 (en) 2007-07-09 2008-07-09 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors

Country Status (2)

Country Link
GB (1) GB0713259D0 (en)
WO (1) WO2009007390A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004953A (en) 2008-11-10 2011-12-14 Vertex Pharma Compounds useful as inhibitors of atr kinase.
MX2011006503A (en) * 2008-12-19 2011-09-06 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase.
US20120159655A1 (en) * 2009-03-13 2012-06-21 Bergen Teknologioverforing As Methods using axl as a biomarker of epithelial-to-mesenchymal transition
DE102009056886A1 (en) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet inhibitors for the treatment of endometriosis
JP2013526539A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazines useful as ATR kinase inhibitors
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2011143425A2 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2011253021A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of ATR kinase
JP2013526538A (en) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CA2803802A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
JP2014520161A (en) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as ATR kinase inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US20130089626A1 (en) 2011-09-30 2013-04-11 Vertex Pharmaceuticals Incorporated Treating Cancer with ATR Inhibitors
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
EP2751099B1 (en) 2011-09-30 2017-06-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2013216006B2 (en) 2012-01-31 2017-06-08 Daiichi Sankyo Company, Limited Pyridone derivatives
PL2833973T3 (en) 2012-04-05 2018-02-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PL3808749T3 (en) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
CA2929188C (en) 2013-11-20 2022-08-09 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
BR112016012146B1 (en) 2013-11-27 2022-11-01 Signalchem Lifesciences Corporation AMINOPYRIDINE DERIVATIVE COMPOUNDS AS KINASE INHIBITORS OF THE TAM FAMILY, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS AND THERAPEUTIC USE THEREOF
BR112016012734B1 (en) 2013-12-06 2022-09-13 Vertex Pharmaceuticals Incorporated COMPOUND OF 2-AMINO-6-FLUORINE-N-[5-FLUORINE-PYRIDIN-3-IL]PYRAZOLE[1,5-A]PYRIMIDIN-3-CARBOXAMIDE, SOLID FORMS, COMPOSITION, USE AND PROCESS FOR THE PREPARATION OF SUCH COMPOUND
US20170027940A1 (en) * 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
ES2667424T3 (en) 2014-04-24 2018-05-10 Novartis Ag Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors
BR112016024484A2 (en) 2014-04-24 2017-08-15 Novartis Ag aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
RU2719583C2 (en) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Radiolabelled 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]-pyrazolo [1, 5-a] pyrimidine-3-carboxamide derivatives used as atr kinase inhibitor, preparations based thereon compounds and various solid forms thereof
DK3157566T3 (en) 2014-06-17 2019-07-22 Vertex Pharma METHOD OF TREATING CANCER USING A COMBINATION CHK1 AND ATR INHIBITORS
TWI723572B (en) 2014-07-07 2021-04-01 日商第一三共股份有限公司 Pyridone derivatives containing tetrahydropyranylmethyl group and use thereof
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
JP6885390B2 (en) 2016-02-26 2021-06-16 小野薬品工業株式会社 A drug for the treatment of cancer, which comprises administering a combination of an Axl inhibitor and an immune checkpoint inhibitor.
EP3673907A4 (en) 2017-08-23 2020-08-19 ONO Pharmaceutical Co., Ltd. Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
TWI827583B (en) 2018-03-08 2024-01-01 美商英塞特公司 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-γ INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2004084813A2 (en) * 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
WO2008038010A1 (en) * 2006-09-30 2008-04-03 Vernalis (R & D) Limited Pyrazine derivatives and their use in therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066629A2 (en) * 2002-02-06 2003-08-14 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
WO2004084813A2 (en) * 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
WO2008038010A1 (en) * 2006-09-30 2008-04-03 Vernalis (R & D) Limited Pyrazine derivatives and their use in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. J. BAMFORD ET AL.: "(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors", BIOORG. MED. CHEM. LETT., vol. 15, 9 June 2005 (2005-06-09), pages 3402 - 3406, XP002500545 *

Also Published As

Publication number Publication date
WO2009007390A2 (en) 2009-01-15
GB0713259D0 (en) 2007-08-15

Similar Documents

Publication Publication Date Title
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
MX2009002010A (en) Heteroaryl derivatives as protein kinase inhibitors.
WO2009007749A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
UA99617C2 (en) Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
SG170069A1 (en) Quinoline derivatives
WO2008032072A8 (en) 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
IN2012DN02577A (en)
WO2008135791A8 (en) Imidazoquinolines with immuno-modulating properties
MY148634A (en) Pyridazinone derivatives
WO2013004995A8 (en) Pyrimidinone compounds and their use
NO20090631L (en) Morpholine pyrimidine derivatives useful in the treatment of proliferative disorders
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
WO2010099379A8 (en) Jak kinase modulating quinazoline derivatives and methods of use thereof
MX2009010047A (en) Chemical compounds.
MX2009010045A (en) Chemical compounds.
AU2009282962A8 (en) Compounds as kinase inhibitors
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
TW200639156A (en) New compounds
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
MX2012008328A (en) Pyrazine derivatives.
MX2012002327A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08786005

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08786005

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载